Roche Q1: oncology and Tamiflu drive sales growth
This article was originally published in Scrip
Executive Summary
For the first quarter 2013, Roche's group sales at CER increased by 6% to CHF11.6 billion while pharmaceutical sales rose by 7% to CHF9.2 billion, driven by cancer medicies and Tamiflu.